Trials / Completed
CompletedNCT05025410
Remimazolam and Remifentanil Without Neuromuscular Blocking Agent
General Anesthesia Using Remimazolam and Remifentanil Without Neuromuscular Blocking Agent: Prospective Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Seoul National University Bundang Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Remimazolam is a novel drug approved for induction and maintenance of general anesthesia. This study aims to check the appropriate dose and patient response by administering remimazolam and remifentanil in surgery that does not require a neuromuscular blocking agents.
Conditions
- Myoma;Uterus
- Polyp Endometrium
- Unspecified Condition Associated With Female Genital Organs and Menstrual Cycle
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remimazolam | Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2022-01-31
- Completion
- 2022-01-31
- First posted
- 2021-08-27
- Last updated
- 2022-04-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05025410. Inclusion in this directory is not an endorsement.